Neureka for Epilepsy
Epilepsy care reimagined
Overview
Raised: $87,101
Rolling Commitments ($USD)
04/29/2023
$1,452
100
2018
Healthcare & Pharmaceuticals
HealthTech
B2B/B2C
Low
Low
Summary Profit and Loss Statement
FY 2021 | FY 2020 | |
---|---|---|
Revenue |
$0 |
$0 |
COGS |
$0 |
$0 |
Tax |
$0 |
$0 |
| ||
| ||
Net Income |
$-1,393,497 |
$-962,316 |
Summary Balance Sheet
FY 2021 | FY 2020 | |
---|---|---|
Cash |
$281,299 |
$64,459 |
Accounts Receivable |
$0 |
$0 |
Total Assets |
$286,340 |
$71,179 |
Short-Term Debt |
$50,065 |
$34,704 |
Long-Term Debt |
$20,171 |
$42,167 |
Total Liabilities |
$70,236 |
$76,871 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual